Printer Friendly

Quagen Pharma.

WEST CALDWELL, N.J. -- Quagen Pharma is a new privately held generic pharmaceutical development company and manufacturer. Led by Ashish Shah, Quagen Pharma's president and chief executive officer, the company started operations in May 2016 with the acquisition and construction of three state-of-the-art, fully functional and Food and Drug Administration- and Drug Enforcement Administration-approved research and development, cGMP (current Good Manufacturing Practices) manufacturing and packaging facilities, all located here. Current combined size of all renovated facilities is about 170,000 square feet.

The company headquarters in West Caldwell is a 55,000-square-foot structure with two stories. It is dedicated to analytical, microbiology, R&D and quality control. The company another 65,000-square-foot facility dedicated to topical creams, lotions, ointment and solutions and oral liquids as well as transdermal patch capabilities in the future. Quagen's third location occupies 51,000 square feet and is dedicated to oral solids with extended and sustained-release capabilities and solids with solvent capabilities.

Quagen's experienced, dedicated and proven management team, along with its qualified and experienced in-house scientific and technical staff, all with Ph.D., MS or BS degrees in pharmaceutical sciences, including pharmacists, engineers and other STEM program graduates, are the key to Quagen's strong future. Consistent internal ANDA (Abbreviated New Drug Application) filings of complex generic products support Quagen's mission and dedication to develop, manufacture and distribute high-quality, safe, effective and affordable prescription and over-the-counter liquids, topicals, semisolid and solid dosage medications, from schedule Cl to CV controlled products while maintaining the highest standards of quality in compliance with cGMPs. Please contact us to find out more about our recent and expected FDA approvals and capabilities.

11 Patton Drive

West Caldwell, N J. 07006

Key contact:

Mike Lupo

Vice President, Sales and Marketing

Phone: (973) 533-8226

quagenpharma.com

COPYRIGHT 2019 Racher Press, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:GENERIC DRUGS REPORT: PROFILES
Publication:Chain Drug Review
Geographic Code:1U2NJ
Date:Sep 23, 2019
Words:294
Previous Article:Ascend Laboratories LLC.
Next Article:Hikma Pharmaceuticals USA.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters